iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25
- Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025
- Completed enrollment of second dose cohort of EOS-984 + pembrolizumab combination in ongoing Phase 1 trial
- EOS-215 Phase 1 trial TRM-010 patient enrollment anticipated to begin in 2Q25
- Cash balance and investment balance of $655.0 million as of December 31, 2024 expected to provide runway through 2027

Read more at globenewswire.com